skip to Main Content
Get your free newsletter: Actionable insight each morning for self-directed investors. 
Home » UK Shares » AIM Risers and Fallers » AIM round-up: Borders & Southern, Argos Resources, ITM Power

Despite another move higher for oil and a shaky start to the day across the Atlantic, London’s junior market managed to quickly recover opening losses and then spend the bulk of the session trading fractionally in the black. At 4.30pm, the AIM Index was three points higher at 961.84.

  • Borders & Southern +94%
  • Argos Resources +61%
  • ITM Power +15%
  • Sunrise Resources -29%
  • Destiny Pharma -28%

The pricing is a bit sketchy but Borders and Southern [LON:BOR] appear to have topped the table today, with the share price having close on doubled by the bell. However, that does come with a wide spread and against unremarkable volumes. There’s no formal news here and although we have that reported pivot away from Russia as a fuel supplier to Europe, that in isolation probably can’t justify the move.

Argos Resources [LON:ARG] also fared well, adding 68% by the close. This is however a microcap of a company valued at just £6m and finished with a 25% spread. Again there’s that fervour over energy stocks well away from Russia and with the company’s focus on the North Falklands, it arguably couldn’t be any more distant, but it all seems a bit speculative right now.

A notable mention for ITM Power [LON:ITM], which added 15% on the day but is now up around 80% from those lows of three weeks back. In terms of state intervention to break the link with Russian energy supplies, putting funding behind green initiatives like this will arguably be way more palatable to the electorate than restarting fossil fuel projects…

It was Sunrise Resources [LON:SRES] which found itself at the foot of the table, off 29% following an update this morning. The aggregate mining company has abandoned talks with a potential partner and whilst other replacement options exist, the market clearly found little to cheer here.

Biotech Destiny Pharma [LON:DEST] also struggled, shedding 28% in the wake of news that the company had undertaken a discounted placing. The sell-off matches the discount, with the proceeds being used to continue progress of clinical assets towards stage 3 trials. Arguably the balanced response to the placing suggests shareholders, whilst supportive, understand that there’s still a lot to be done.

Related

This article is not investment advice. Investors should do their own research or consult a professional advisor.

Tony Cross

Tony Cross

Tony Cross is a market commentator with over 15 years of experience, producing compelling, insightful copy for journalists and investors alike. Focusing on macroeconomics, UK blue chip equities and inter market analysis, Cross's commentary is well regarded for its clarity and ability to cut through the waffle. He has been quoted in publications as diverse as The Financial Times, The Times, The Guardian and The Sun. He has also been a regular guest on both Share Radio and TipTV.

Stocks in Focus

Here are some of the smaller companies we follow most closely. They represent significant growth stories in our view. Our in-depth reports detail why we like them.

Comments

Subscribe for more stories like this, 8am weekdays - for free!


Get your free daily newsletter: 

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

Pepperstone
FP Markets
IG
Spreadex
WisdomTree
ActivTrades
Back To Top